Romosozumab was not associated with increased cardiovascular risks among patients with osteoporosis when compared with bisphosphonate use. Romosozumab does not appear to significantly increase the ...

Evenity is a brand of the drug romosozumab, which is known as a monoclonal ... They are both given as a subcutaneous injection. The most common side effects for Evenity are joint pain and ...

Like teriparatide, it is administered by self-injection once a day, while romosozumab is given as a monthly shot by a healthcare professional. Professor Jonathan Benger, chief medical officer and ...

New data from multiple countries confirm the effectiveness of romosozumab, the dual-acting osteoporosis treatment that increases bone formation and decreases bone resorption. Findings were presented ...

Medscape News UK, February 12, 2025 Romosozumab Improves Bone Strength in Women With T2D Romosozumab plus alendronate led to a greater improvement in bone strength than alendronate alone in ...